Protara Therapeutics (TARA) Interest Expenses (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Interest Expenses data on file, last reported at $8.8 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 109.33% year-over-year to $8.8 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a 109.33% increase from a year earlier, with the FY2025 full-year figure at $83.6 million, up 15.31% from the prior year.
• Interest Expenses for Q1 2026 stood at $8.8 million, up from $357000.0 in the prior quarter.
• Over the last five years, Interest Expenses for TARA reached as high as $8.8 million in Q1 2026 and fell as low as $239000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $2.5 million across 5 years, with a median of $1.4 million in 2023.
• On a YoY basis, Interest Expenses climbed as much as 2782.0% in 2022 and fell as far as 85.59% in 2022.
• Year by year, Interest Expenses stood at $332000.0 in 2022, then dropped by 28.01% to $239000.0 in 2023, then soared by 38.91% to $332000.0 in 2024, then advanced by 7.53% to $357000.0 in 2025, then soared by 2376.75% to $8.8 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $8.8 million in Q1 2026, $357000.0 in Q4 2025, and $5.0 million in Q3 2025.